5:24 PM
 | 
Jun 24, 2014
 |  BC Extra  |  Clinical News

Ohr falls on AMD data

Ohr Pharmaceutical Inc. (NASDAQ:OHRP) fell $3.66 (32%) to $7.74 on Tuesday after interim Phase II data showed its squalamine eye drops ( OHR-002) for wet age-related macular degeneration failed to significantly improve...

Read the full 155 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >